Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-305.52m
- Incorporated2020
- Employees5.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
enVVeno Medical Corp | 0.00 | -20.60m | 56.12m | 31.00 | -- | 1.11 | -- | -- | -1.43 | -1.43 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -56.37 | -58.43 | -59.43 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Prenetics Global Ltd | 22.25m | -49.97m | 56.20m | 320.00 | -- | 0.2453 | -- | 2.53 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
Kezar Life Sciences Inc | 7.00m | -98.57m | 56.47m | 58.00 | -- | 0.3744 | -- | 8.07 | -1.35 | -1.35 | 0.0962 | 2.07 | 0.0316 | -- | -- | 120,689.70 | -44.47 | -32.54 | -47.84 | -34.09 | -- | -- | -1,408.11 | -4,308.11 | -- | -- | 0.0634 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 57.26m | 12.00 | -- | 5.63 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Mural Oncology PLC | 0.00 | -173.30m | 58.10m | 117.00 | -- | 0.2822 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Enzo Biochem Inc | 33.34m | -17.55m | 58.15m | 179.00 | -- | 0.8386 | -- | 1.74 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
Omega Therapeutics Inc | 6.31m | -78.90m | 59.02m | 93.00 | -- | 2.25 | -- | 9.35 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -305.52m | 59.28m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Kronos Bio Inc | 8.41m | -102.85m | 59.69m | 58.00 | -- | 0.4845 | -- | 7.10 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
Aerovate Therapeutics Inc | 0.00 | -87.94m | 60.04m | 51.00 | -- | 0.6358 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Bioqual Inc | 62.86m | 957.02k | 60.37m | 108.00 | 63.08 | 1.55 | 17.21 | 0.9604 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Maia Biotechnology Inc | 0.00 | -28.08m | 61.44m | 13.00 | -- | 19.29 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
Serina Therapeutics Inc | 179.00k | -18.67m | 61.55m | 4.00 | -- | -- | -- | 343.85 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Allakos Inc | 0.00 | -206.00m | 62.14m | 131.00 | -- | 0.7398 | -- | -- | -2.35 | -2.35 | 0.00 | 0.9454 | 0.00 | -- | -- | 0.00 | -86.62 | -42.71 | -99.21 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
Reneo Pharmaceuticals Inc | 0.00 | -56.54m | 62.34m | 8.00 | -- | 0.8109 | -- | -- | -16.82 | -16.82 | 0.00 | 23.00 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 3.68m | 9.39% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 751.75k | 1.92% |
Ikarian Capital LLCas of 31 Mar 2024 | 257.98k | 0.66% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 247.92k | 0.63% |
Geode Capital Management LLCas of 30 Jun 2024 | 186.86k | 0.48% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 169.16k | 0.43% |
Formidable Asset Management LLCas of 30 Jun 2024 | 113.64k | 0.29% |
Qube Research & Technologies Ltd.as of 31 Mar 2024 | 59.82k | 0.15% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 59.55k | 0.15% |
Millennium Management LLCas of 31 Mar 2024 | 55.99k | 0.14% |